Loading company
DNA X, Inc.
SONM · Nasdaq · ·
Next earnings: October 30, 2026
$4.33+0.5%Sep 29 close
- 1M
- +25.1%
- 6M
- +10.5%
- 1Y
- -60.2%
- 5Y
- -99.1%
DNA X, Inc. is the 78th largest of 84 graded companies. Showing 5 of them, including SONM itself. 12 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| PJT Partners Inc.PJT | A+ | — | $1.9B | 10.6% | $661.8M | — |
| Morgan StanleyMS | A | $302.8B | $78B | 25.8% | -$18.6B | 15.59 |
| The Goldman Sachs Group, Inc.GS | B | $266.8B | $66.2B | 31.7% | -$41.5B | 14.15 |
| Schwab Charles Corp.SCHW | A+ | $171.4B | $26B | 38.8% | $10.8B | 18.05 |
| DNA X, Inc.SONM | D | $6.4M | $59.4M | -14.4% | -$8.7M | — |
79 more capital markets companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded DNA X, Inc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
SONM · Nasdaq · ·
Next earnings: October 30, 2026
$4.33+0.5%Sep 29 close